E8 Funding, recognized as a reputable proprietary trading firm, extends its offerings to traders through the innovative ELEV8 account, alongside its standard two-step evaluation process. Founded on November 5, 2021, with establishments in both Dallas, Texas, USA, and Prague, Czech Republic, E8 Funding continues to expand its global footprint, providing traders with ample opportunities to showcase their skills and achieve funding.
ELEV8 Account: Elevating Trading Opportunities
The ELEV8 account, while mirroring the foundational structure of basic E8 Funding accounts, distinguishes itself through exclusive features and benefits. Designed for traders seeking significant trading capital, the ELEV8 account starts at a $100,000 balance, in contrast to the four-tiered structure ($25,000; $50,000; $100,000; $250,000) of basic accounts. The evaluation challenge for the ELEV8 account comprises two steps, each with specific targets and limits:
Step 1:
- Profit target of 8%
- Daily loss limit of 5% (Daily floating loss + closed loss)
- Maximum initial deposit loss of 8%
- Duration ranges from a minimum of 1 day to a maximum of 30 days
Step 2:
- Profit target of 5%
- Maximum daily loss of 5% (Daily floating loss + closed loss)
- Maximum initial deposit loss of 8%
- Duration ranges from a minimum of 1 day to a maximum of 60 days
Upon the successful completion of these steps, traders are awarded a $100,000 funded ELEV8 account, qualifying for an 80% profit split. A standout feature of the ELEV8 account is its scalability, offering the potential to increase the account balance up to $1,000,000, an opportunity not available with basic accounts.
This initiative by E8 Funding not only enhances the trading landscape but also opens doors for traders to achieve and manage larger funds under the firm’s supportive framework.
For more insights into the ELEV8 account and its scaling plan, keep an eye on upcoming posts. Meanwhile, detailed information about E8 Funding and its offerings can be found on their website or through our comprehensive review.
